Welcome toVacV Biotherapeutics
VacV is a cancer immunotherapy company developing viral-based therapies for cancer. Our versatile technology uses a novel oncolytic Vaccinia virus and is designed to create efficacious and safe treatments. Our promising pipeline of easy-to-administer treatments includes features that offer significant advantages compared to existing treatment options.
We’re developing the next generation of cancer immunotherapies using our modified oncolytic Vaccina virus technology to promote a durable anti-tumor response following systemic delivery.
Executive Chairman’s company statement
“The VacV team is developing a pipeline of immunotherapies for cancer using a novel oncolytic Vaccinia virus technology based on over 20 years of ground-breaking research at one of the UK’s leading cancer research centers. Our enhanced systemic delivery platform addresses many of the historic challenges faced by oncolytic viruses and allows efficient targeting of tumor cells anywhere in the body.”
Glyn Edwards – Executive Chairman
SUB HEADING HERE
VacV Biotherapeutics (“VacV” or “the Company”), a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its promising pipeline of pre-clinical assets with best-in-class potential, towards the clinic.